

of all documents filed by the applicant and by all other parties.

Tracking the Proceeding

Throughout the proceeding, additional information about the project will be available from the Commission's Office of External Affairs, at (866) 208-FERC, or on the FERC website at www.ferc.gov using the "eLibrary" link as described above. The eLibrary link also provides access to the texts of all formal documents issued by the Commission, such as orders, notices, and rulemakings.

In addition, the Commission offers a free service called eSubscription which allows you to keep track of all formal issuances and submittals in specific dockets. This can reduce the amount of time you spend researching proceedings by automatically providing you with notification of these filings, document summaries, and direct links to the documents. For more information and to register, go to www.ferc.gov/docs-filing/esubscription.asp.

Intervention Deadline: 5 p.m. Eastern Time on April 3, 2025.

Dated: March 13, 2025.

Debbie-Anne A. Reese,
Secretary.

[FR Doc. 2025-04702 Filed 3-19-25; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 15320-001]

Stirling T. Hebenstreit; Notice of Preliminary Permit Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Competing Applications

On June 24, 2024, and as supplemented on October 16, 2024, and December 31, 2024, Stirling T. Hebenstreit, filed an application for a preliminary permit, pursuant to section 4(f) of the Federal Power Act (FPA), proposing to study the feasibility of the Energy Production from Deep Ocean Pressure Project No. 15320 (project), to be located on Commencement Bay in Pierce County, Washington. The sole purpose of a preliminary permit, if issued, is to grant the permit holder priority to file a license application during the permit term. A preliminary permit does not authorize the permit holder to perform any land-disturbing activities or otherwise enter upon lands or waters owned by others without the owners' express permission.

The proposed project would consist of the following: (1) a 65-foot long, 25-foot-wide, 11-foot-high single-haul floating steel barge (surface platform), moored to the seafloor using anchors and mooring buoys; (2) a 1-inch diameter, 575-foot-long stainless-steel screw gate valve stem rod descending from the surface platform to an intake opening gate; (3) a 4-foot-diameter vertical intake opening with an adjustable gate valve located at a depth of about 560 feet from the water surface; (4) a 3-foot-long, 4- to 8-foot-diameter vertical intake raceway pipe; (5) an axial turbine with 3- to 4-foot-long turbine blades housed within the intake raceway and connected to a submerged 4-foot-long, 4-foot-wide, 6-foot-high hermetically-sealed stainless-steel box containing a single 1.67-megawatt (MW) generator; (6) two 20-foot-long, 8.5-foot-wide, 8-foot-high, aluminum tanks situated on the seafloor that receive water exiting the turbine; (7) air compressors connected to hoses and air actuators to control the flow of turbine discharge water into and between the tanks; (8) six 1.33-foot-diameter outlet pipes that discharge water from the tanks to the sea; (9) two 560-foot-long steel pipe raceways containing a total of five 1-inch diameter, 560-foot-long aluminum-core conductor cables to transmit electricity from the generator to two 10 megawatt-hour sodium-ion energy storage battery banks located on the floating surface platform; and (10) appurtenant facilities. Battery banks would be transported to and from the surface platform and the Port of Tacoma using a supply vessel. The estimated annual generation of the project would be about 827,542 megawatt-hours.

Applicant Contact: Stirling T. Hebenstreit, Stirling Industries LLC, 3303 Paty Drive, Honolulu, Hawaii 96822; telephone at (571) 535-5966.

FERC Contact: John Matkowski; phone (202) 502-8576; email at john.matkowski@ferc.gov.

Deadline for filing comments, motions to intervene, competing applications (without notices of intent), or notices of intent to file competing applications: 60 days from the issuance of this notice. Competing applications and notices of intent must meet the requirements of 18 CFR 4.36.

The Commission strongly encourages electronic filing. Please file comments, motions to intervene, notices of intent, and competing applications using the Commission's eFiling system at <https://ferconline.ferc.gov/FERCOOnline.aspx>. Commenters can submit brief comments up to 6,000 characters, without prior registration, using the eComment system at <https://ferconline.ferc.gov/asp>. For

assistance, please contact FERC Online Support at FERCOOnlineSupport@ferc.gov, (866) 208-3676 (toll free), or (202) 502-8659 (TTY). In lieu of electronic filing, you may submit a paper copy. Submissions sent via the U.S. Postal Service must be addressed to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 888 First Street NE, Room 1A, Washington, DC 20426. Submissions sent via any other carrier must be addressed to: Debbie-Anne A. Reese, Secretary, Federal Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland 20852. The first page of any filing should include docket number P-15320-001.

The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, community organizations, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502-6595 or OPP@ferc.gov.

More information about this project, including a copy of the application, can be viewed on the Commission's website (<https://www.ferc.gov>) using the "eLibrary" link. Enter the docket number (P-15320) in the docket number field to access the document. For assistance, please contact FERC Online Support.

Dated: March 13, 2025.

Debbie-Anne A. Reese,
Secretary.

[FR Doc. 2025-04698 Filed 3-19-25; 8:45 am]

BILLING CODE 6717-01-P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal

Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than April 4, 2025.

A. *Federal Reserve Bank of Kansas City* (Jeffrey Imgarten, Assistant Vice President), 1 Memorial Drive, Kansas City, Missouri, 64198-0001. Comments can also be sent electronically to KCApplicationComments@kc.frb.org:

1. *Emma Ryan, Heartwell, Nebraska*; to join the Ryan Family Group, a group acting in concert, to acquire voting shares of First Central Nebraska Co., and thereby indirectly acquire voting shares of Nebraska State Bank and Trust Company, both of Broken Bow, Nebraska.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2025-04781 Filed 3-19-25; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0150]

Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Beckman Coulter, Inc., for the Access SARS-CoV-2 IgG, Access SARS-CoV-2 IgM, and Access SARS-CoV-2 IgG II tests. FDA revoked the Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.

DATES: The revocation of the Authorization for the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgG, Access SARS-CoV-2 IgM, and Access SARS-CoV-2 IgG II tests are effective as of January 8, 2025.

ADDRESSES: Submit written requests for a single copy of the revocations to the Office of Policy, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the revocations may be sent. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the revocations.

FOR FURTHER INFORMATION CONTACT: Kim Sapsford-Medintz, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 3216, Silver Spring, MD 20993-0002, 301-796-0311 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION:

I. Background

Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) as amended by the Project BioShield Act of 2004 (Pub. L. 108-276) and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5) allows FDA to strengthen the public health protections against biological, chemical, radiological, or nuclear agent or agents. Among other things, section 564 of the FD&C Act allows FDA to authorize the use of an unapproved medical product or an unapproved use of an approved medical product in certain situations.

On June 26, 2020, FDA issued the Authorization to Beckman Coulter, Inc., for the Access SARS-CoV-2 IgG test, subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on November 20, 2020

(85 FR 74346), as required by section 564(h)(1) of the FD&C Act.

On October 8, 2020, FDA issued the Authorization to Beckman Coulter, Inc., for the Access SARS-CoV-2 IgM test, subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on April 23, 2021 (86 FR 21749), as required by section 564(h)(1) of the FD&C Act.

On March 22, 2021, FDA issued the Authorization to Beckman Coulter, Inc., for the Access SARS-CoV-2 IgG II test, subject to the terms of the Authorization. Notice of the issuance of this Authorization was published in the **Federal Register** on July 23, 2021 (86 FR 39040), as required by section 564(h)(1) of the FD&C Act.

Subsequent updates to the Authorizations were made available on FDA's website. The authorization of a device for emergency use under section 564 of the FD&C Act may, pursuant to section 564(g)(2) of the FD&C Act, be revoked when the criteria under section 564(c) of the FD&C Act for issuance of such authorization are no longer met (section 564(g)(2)(B) of the FD&C Act), or other circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the FD&C Act).

II. Authorizations Revocation Requests

In a request received by FDA on November 22, 2024, Beckman Coulter, Inc., requested the revocation of, and on January 8, 2025, FDA revoked, the Authorization for the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgG test. Beckman Coulter, Inc., notified FDA of their intent to discontinue distribution of the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgG test as of January 1, 2025, and requested FDA revoke the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgG test. FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization.

In a request received by FDA on November 22, 2024, Beckman Coulter, Inc., requested the revocation of, and on January 8, 2025, FDA revoked, the Authorization for the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgM test. Beckman Coulter, Inc., notified FDA of their intent to discontinue distribution of the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgM test as of January 1, 2025, and requested FDA revoke the Beckman Coulter, Inc.'s Access SARS-CoV-2 IgM test. FDA has determined that it is appropriate to protect the public health or safety to revoke this Authorization.